

## DAFTAR PUSTAKA

- Anders, C. and Carey, L. 2019. ER/PR negative, HER2-negative (triple-negative) breast cancer. *Wolters Kluwer*.
- ANTMAN, K., SKARIN, A., MAYER, R., HARGREAVES, H. and CANELLOS, G. 1979. Microangiopathic Hemolytic Anemia and Cancer. *Medicine*, 58(5), pp.377-384.
- Anwar, S., Tampubolon, G., Van Hemelrijck, M., Hutajulu, S., Watkins, J. and Wulaningsih, W., 2018. Determinants of cancer screening awareness and participation among Indonesian women. *BMC Cancer*, 18(1).
- Babalou, A., 2017. The Association of Parity and Breastfeeding with Breast Cancer: A Review. *Health Science Journal*.
- Bain, N., 2000. Treating patients with colorectal cancer in rural and urban areas: a qualitative study of the patients' perspective. *Family Practice*, 17(6), pp.475-479.
- Brewster, A. M., MacGregor, M. C. & Brown, P., 2014. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. *Lancet Oncol*.
- CDC, 2019. *Does Breast or Ovarian Cancer Run in Your Family?*. [Online] Available at: [https://www.cdc.gov/genomics/disease/breast\\_ovarian\\_cancer/breast\\_cancer.htm?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffeatures%2Fhereditarycancer%2Findex.html](https://www.cdc.gov/genomics/disease/breast_ovarian_cancer/breast_cancer.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffeatures%2Fhereditarycancer%2Findex.html) [Accessed November 2019].
- Chen, B., Dai, D., Tang, H., Ai, X., Chen, X., Zhang, X., Li, Z. and Xie, X., 2016. Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. *PLOS ONE*, 11(11), p.e0165133.
- Chen, X., Ye, G., Zhang, C., Li, X. and Shen, K., 2016. Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. *Chinese Journal of Cancer Research*, 28(6), pp.561-569.
- Coleman MP et al. 2008. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*, 9, 730–56.
- Cui, Y., Whiteman, M., Flaws, J., Langenberg, P., Tkaczuk, K. and Bush, T., 2002. Body mass and stage of breast cancer at diagnosis. *International Journal of Cancer*, 98(2), pp.279-283.

- DeVita, V., Rosenberg, S. and Lawrence, T. 2008. *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology*. 8th ed. Philadelphia: Lippincott William & Wilkins.
- Dicato, M., Plawny, L. and Diederich, M. 2010. Anemia in cancer. *Annals of Oncology*, 21, pp.vii167-vii172.
- Ding, W., Li, Z., Wang, C., Dai, J., Ruan, G. and Tu, C., 2018. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer. *Medicine*, 97(42), p.e12908.
- Dunning, F. F., 2015. *A Manual of Laboratory and Diagnostic Tests*. 9th ed. Philadelphia: Lippincott Williams & Wilkins.
- Fei, X., Wu, J., Kong, Z. and Christakos, G. 2015. Urban-Rural Disparity of Breast Cancer and Socioeconomic Risk Factors in China. *PLOS ONE*, 10(2), p.e0117572.
- Haber, G., Ahmed, N. U. & Pekovic, V., 2012. Family History of Cancer and Its Association With Breast Cancer Risk Perception and Repeat Mammography. *NCBI*.
- Henke, M., Sindlinger, F., Ikenberg, H., Gerds, T. and Schumacher, M. 2004. Blood Hemoglobin Level and Treatment Outcome of Early Breast Cancer. *Strahlentherapie und Onkologie*, 180(1), pp.45-51.
- IARC (2008). *World cancer report 2008*. Lyon, International Agency for Research on Cancer
- Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG). *BioMed Research International*, 2019, pp.1-14.
- Indonesia, K. K. R., 2018. *Hasil Utama RISKESDAS 2018*, s.l.: s.n.
- Jee, S., Yun, J., Park, E., Cho, E., Park, I., Sull, J., Ohrr, H. and Samet, J. 2008. Body mass index and cancer risk in Korean men and women. *International Journal of Cancer*, 123(8), pp.1892-1896.
- Kern, P., Kalisch, A., Kolberg, H., Kimmig, R., Otterbach, F., von Minckwitz, G., Sikov, W., Pott, D. and Kurbacher, C., 2013. Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response. *Chemotherapy*, 59(5), pp.387-394.
- Kirshner, J., Hatch, M., Hennessy, D., Fridman, M. and Tannous, R., 2004. Anemia in Stage II and III Breast Cancer Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Chemotherapy. *The Oncologist*, 9(1), pp.25-32.
- Königsberg, R., Pfeiler, G., Klement, T., Hammerschmid, N., Brunner, A., Zeillinger, R., Singer, C. and Dittrich, C. 2012. Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between

- younger (<65) and elderly ( $\geq 65$ ) patients. *European Journal of Cancer*, 48(16), pp.2962-2968.
- Lacey JV Jr. et al. 2009. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. *BMC Cancer*, 9, 84.
- Liao, H., Zhang, W., Sun, J., Li, F., He, Z. and Wu, S. 2018. The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer. *Journal of Cancer*, 9(2), pp.296-303.
- Liebman, H. 2014. Thrombocytopenia in cancer patients. *Thrombosis Research*, 133, pp.S63-S69.
- Liu, K., Zhang, W., Dai, Z., Wang, M., Tian, T., Liu, X., Kang, H., Guan, h., Zhang, S. and Dai, Z. 2018). Association between body mass index and breast cancer risk: evidence based on a dose&ndash;response meta-analysis. *Cancer Management and Research*, Volume 10, pp.143-151.
- Ma, R., Chen, C., Zhang, W., You, J., Huang, D. and Guo, G., 2016. Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer. *Medicine*, 95(13), p.e3240.
- Morceau, F., Dicato, M. and Diederich, M. 2009. Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis. *Mediators of Inflammation*, 2009, pp.1-11.
- National Cancer Registration and Analysis Service, 2009. The effect of rurality on cancer incidence and mortality. National Comprehensive Cancer Network (NCCN), 2012. Breast Cancer 1:BINV-8, BINV-K. In: NCCN clinical practice guidelines in oncology. *National Comprehensive Cancer Network (NCCN)*.
- Neven, P., Brouckaert, Wildiers and Floris. 2012. Update on triple-negative breast cancer: prognosis and management strategies. *International Journal of Women's Health*, p.511.
- Observatory, I. G. C., 2018. *New Global Cancer Data: GLOBOCAN 2018*, Geneva: s.n.
- Palmer, J., Adams-Campbell, L., Boggs, D., Wise, L. and Rosenberg, L. 2007. A Prospective Study of Body Size and Breast Cancer in Black Women. *Cancer Epidemiology Biomarkers & Prevention*, 16(9), pp.1795-1802.
- Peffault de Latour, R., Des Guetz, G., Laurence, V., Palangié, T., Pierga, J., Diéras, V., Jouve, M., Extra, J., Pouillart, P. and Decaudin, D. 2004. Breast Cancer Associated With Idiopathic Thrombocytopenic Purpura. *American Journal of Clinical Oncology*, 27(4), pp.333-336.

- Razzaghdoust, A., Mofid, B. and Zangeneh, M., 2019. Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma. *Journal of Oncology Pharmacy Practice*, 26(3), pp.587-594.
- Singh, M. and Jangra, B., 2013. Association between body mass index and risk of breast cancer among females of north India. *South Asian Journal of Cancer*, 2(3), p.121.
- Song, H., Wu, T., Xie, D., Li, D., Hua, K., Hu, J. and Fang, L. 2018. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer. *Cellular Physiology and Biochemistry*, 48(5), pp.1968-1982.
- H, V., R, K. & Bianchini, F., 2002. Weight Control and Physical Activity In Cancer Prevention. *Eur J Cancer Prev*, Volume 11, pp. S94-S100.
- Schwartzberg, L. S., 2006. Neutropenia: Etiology and Pathogenesis. *Clinical Cornerstone*, Volume 8.
- Tano, S., Kavanaugh, M., Peddi, P., Mansour, R., Shi, R. and Burton, G., 2017. Triple negative breast cancer (TNBC): Analysis of age and stage distribution and survival between African American and Caucasian women in a predominant low-income population. *Journal of Clinical Oncology*, 35(15\_suppl), pp.e12586-e12586.
- Theriault, R., Litton, J., Mittendorf, E., Chen, H., Meric-Bernstam, F., Chavez-MacGregor, M., Morrow, P., Woodward, W., Sahin, A., Hortobagyi, G. and Gonzalez-Angulo, A. 2011. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. *Clinical Breast Cancer*, 11(5), pp.325-331.
- Vieira, R., Biller, G., Uemura, G., Ruiz, C. and Curado, M., 2017. Breast cancer screening in developing countries. *Clinics*, 72(4), pp.244-253.
- Widodo, I., Dwianingsih, E., Triningsih, E., Utoro, T. and Soeripto, S., 2014. Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes. *Asian Pacific Journal of Cancer Prevention*, 15(15), pp.6109-6113.
- Wang, K., Wu, Y., Zhang, X., Chen, L., Zhu, W., Zhang, A., Zheng, K., Yin, X., Li, F., Kong, L., Ma, B., Li, H., Liu, J., Jiang, J., Li, Z., Shi, Y., Ren, G. and Li, H., 2019. Clinicopathologic and Prognostic Significance of Body Mass
- World Health Organization. 2020. *Breast cancer: prevention and control*. [online] Available at: <https://www.who.int/cancer/detection/breastcancer/en/> [Accessed 17 Feb. 2020].